Join Growin Stock Community!

Adial pharmaceuticals, inc.ADIL.US Overview

US StockHealthcare
(No presentation for ADIL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ADIL AI Insights

ADIL Overall Performance

ADIL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ADIL Recent Performance

-2.06%

Adial pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ADIL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ADIL Key Information

ADIL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ADIL Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Price of ADIL

ADIL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ADIL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.63
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.63
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ADIL's latest earnings report released?

    The most recent financial report for Adial pharmaceuticals, inc. (ADIL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADIL's short-term business performance and financial health. For the latest updates on ADIL's earnings releases, visit this page regularly.

  • How much cash does ADIL have?

    At the end of the period, Adial pharmaceuticals, inc. (ADIL) held Total Cash and Cash Equivalents of 4.61M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ADIL's EPS continuing to grow?

    According to the past four quarterly reports, Adial pharmaceuticals, inc. (ADIL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ADIL?

    Adial pharmaceuticals, inc. (ADIL)'s Free Cash Flow (FCF) for the period is -1.83M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ADIL?

    The latest valuation data shows Adial pharmaceuticals, inc. (ADIL) has a Price-To-Earnings (PE) ratio of -0.95 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.